Adial Pharmaceuticals (ADIL) Change in Account Payables (2019 - 2026)
Adial Pharmaceuticals (ADIL) posted Change in Account Payables of -$81640.0 for Q1 2026, down 126.67% sequentially from $306154.0 in Q3 2025, and down 128.92% YoY from $282300.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Change in Account Payables (2019 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Change in Account Payables for 8 years, with the latest figure at -$81640.0 in Q1 2026.
- Quarterly Change in Account Payables fell 128.92% year-over-year to -$81640.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $645502.0 (up 198.27% YoY) and the FY2024 annual result came in at -$47942.0, down 299.24% from the prior year.
- Change in Account Payables eased to -$81640.0 in Q1 2026 per ADIL's latest filing, from $306154.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $306154.0 in Q3 2025 and troughed at -$255823.0 in Q2 2023.
- A 5-year average of $41300.4 and a median of $29978.0 in 2022 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 20447.26% in 2023, down 192.65% in 2023.
- Over 5 years, Change in Account Payables stood at $1077.0 in 2022, then jumped by 20447.26% to $221294.0 in 2023, then tumbled by 117.15% to -$37942.0 in 2024, then soared by 906.9% to $306154.0 in 2025, then sank by 126.67% to -$81640.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$81640.0, $306154.0, and $138688.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 1.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81,640.00 |
| Mar 31, 2026 | -81,640.00 |
| Sep 30, 2025 | 306,154.00 |
| Sep 30, 2025 | 306,154.00 |
| Jun 30, 2025 | 138,688.00 |
| Jun 30, 2025 | 138,688.00 |
| Mar 31, 2025 | 282,300.00 |
| Mar 31, 2025 | 282,300.00 |
| Sep 30, 2024 | -37,942.00 |
| Sep 30, 2024 | -37,942.00 |
| Jun 30, 2024 | -102,085.00 |
| Jun 30, 2024 | -102,085.00 |
| Mar 31, 2024 | 74,143.00 |
| Mar 31, 2024 | 74,143.00 |
| Dec 31, 2023 | 221,294.00 |
| Dec 31, 2023 | 221,294.00 |
| Sep 30, 2023 | -27,776.00 |
| Sep 30, 2023 | -27,776.00 |
| Jun 30, 2023 | -255,823.00 |
| Jun 30, 2023 | -255,823.00 |